Squarepoint Ops LLC Has $530,000 Stock Position in Personalis, Inc. (NASDAQ:PSNL)

Squarepoint Ops LLC boosted its stake in shares of Personalis, Inc. (NASDAQ:PSNL - Free Report) by 438.7% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 91,684 shares of the company's stock after purchasing an additional 74,664 shares during the period. Squarepoint Ops LLC owned about 0.13% of Personalis worth $530,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in PSNL. Point72 Asia Singapore Pte. Ltd. bought a new stake in Personalis in the fourth quarter worth approximately $28,000. JPMorgan Chase & Co. grew its position in Personalis by 2,827.0% in the fourth quarter. JPMorgan Chase & Co. now owns 5,854 shares of the company's stock worth $34,000 after acquiring an additional 5,654 shares in the last quarter. Olympiad Research LP bought a new stake in Personalis in the fourth quarter worth approximately $59,000. Alpine Global Management LLC bought a new stake in Personalis in the fourth quarter worth approximately $60,000. Finally, SG Americas Securities LLC bought a new stake in Personalis in the fourth quarter worth approximately $63,000. 61.91% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

PSNL has been the subject of several recent research reports. Guggenheim initiated coverage on shares of Personalis in a research report on Thursday, May 15th. They issued a "buy" rating and a $6.00 target price for the company. Craig Hallum initiated coverage on shares of Personalis in a report on Monday, March 17th. They set a "buy" rating and a $8.00 price objective for the company. HC Wainwright upped their price objective on shares of Personalis from $8.00 to $9.00 and gave the stock a "buy" rating in a report on Wednesday, May 7th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $7.00 price objective on shares of Personalis in a report on Thursday, April 10th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $7.67.

Personalis Price Performance

Shares of NASDAQ PSNL traded down $0.09 during trading hours on Thursday, hitting $5.06. 972,268 shares of the stock were exchanged, compared to its average volume of 1,023,437. The firm has a market capitalization of $446.92 million, a P/E ratio of -3.01 and a beta of 1.83. Personalis, Inc. has a one year low of $1.14 and a one year high of $7.20. The company's 50 day moving average is $4.06 and its 200 day moving average is $4.46.

Personalis (NASDAQ:PSNL - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.05. The firm had revenue of $20.61 million during the quarter, compared to analysts' expectations of $17.41 million. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. Research analysts anticipate that Personalis, Inc. will post -1.4 earnings per share for the current fiscal year.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.